Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06134648 · ClinicalTrials.gov registry record · Phase 1
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 646
- Enrollment target
NCT06134648 is a Phase 1 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 646 participants.
The verdict
NCT06134648, a Phase 1 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 646 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL RSV/hMPV vaccine candidate Dose L
- BIOLOGICAL RSV/hMPV vaccine candidate Dose A
- BIOLOGICAL RSV/hMPV vaccine candidate Dose B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2026-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06134648
The ClinicalTrials.gov registry entry for NCT06134648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06134648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06134648 about?
NCT06134648 is a clinical study titled "Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate". The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will eval...
What is the current status of trial NCT06134648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 646 participants. The study started on 2023-11-01. Estimated completion is 2026-02-27.
What interventions are being tested in trial NCT06134648?
The interventions under investigation include: Placebo (BIOLOGICAL), RSV/hMPV vaccine candidate Dose L (BIOLOGICAL), RSV/hMPV vaccine candidate Dose A (BIOLOGICAL), RSV/hMPV vaccine candidate Dose B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06134648?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.